Jonathan Symonds - Net Worth and Insider Trading
Jonathan Symonds Net Worth
The estimated net worth of Jonathan Symonds is at least $1,425 dollars as of 2025-03-25. Jonathan Symonds is the Director of Rubius Therapeutics Inc and owns about 25,000 shares of Rubius Therapeutics Inc (RUBY) stock worth over $1,425. Details can be seen in Jonathan Symonds's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jonathan Symonds has not made any transactions after 2018-07-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jonathan Symonds
Jonathan Symonds Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jonathan Symonds owns 2 companies in total, including Rubius Therapeutics Inc (RUBY) , and Innocoll Holdings PLC (INNL) .
Click here to see the complete history of Jonathan Symonds’s form 4 insider trades.
Insider Ownership Summary of Jonathan Symonds
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RUBY | Rubius Therapeutics Inc | 2018-07-20 | director |
| INNL | Innocoll Holdings PLC | 2017-07-24 | director |
Jonathan Symonds Latest Holdings Summary
Jonathan Symonds currently owns a total of 1 stock. Jonathan Symonds owns 25,000 shares of Rubius Therapeutics Inc (RUBY) as of July 20, 2018, with a value of $1,425.
Latest Holdings of Jonathan Symonds
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RUBY | Rubius Therapeutics Inc | 2018-07-20 | 25,000 | 0.06 | 1,425 |
Holding Weightings of Jonathan Symonds
Jonathan Symonds Form 4 Trading Tracker
According to the SEC Form 4 filings, Jonathan Symonds has made a total of 0 transactions in Rubius Therapeutics Inc (RUBY) over the past 5 years. The most-recent trade in Rubius Therapeutics Inc is the acquisition of 25,000 shares on July 20, 2018, which cost Jonathan Symonds around $575,000.
Insider Trading History of Jonathan Symonds
- 1
Jonathan Symonds Trading Performance
GuruFocus tracks the stock performance after each of Jonathan Symonds's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jonathan Symonds is -35.46%. GuruFocus also compares Jonathan Symonds's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jonathan Symonds within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jonathan Symonds's insider trading performs compared to the benchmark.
Performance of Jonathan Symonds
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -14.58 | | | | | |
| Relative Return to S&P 500(%) | -16.55 | | | | | |
Jonathan Symonds Ownership Network
Ownership Network List of Jonathan Symonds
Ownership Network Relation of Jonathan Symonds
Jonathan Symonds Owned Company Details
What does Rubius Therapeutics Inc do?
Who are the key executives at Rubius Therapeutics Inc?
Jonathan Symonds is the director of Rubius Therapeutics Inc. Other key executives at Rubius Therapeutics Inc include CEO and President Dannielle Appelhans , director & Chief Executive Officer Pablo J Cagnoni , and Chief Scientific Officer Laurence A. Turka .
Rubius Therapeutics Inc (RUBY) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Rubius Therapeutics Inc (RUBY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rubius Therapeutics Inc (RUBY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Rubius Therapeutics Inc (RUBY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rubius Therapeutics Inc Insider Transactions
Jonathan Symonds Mailing Address
Above is the net worth, insider trading, and ownership report for Jonathan Symonds. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Jonathan Symonds's mailing address is: Newtown Square Pa 19073.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
